Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
RPM International Director Frederick R. Nance Sells $197K of Stock
Frederick R. Nance, Director, sold 1,896 shares of RPM International Inc at $103.97 a share, worth $197K in total on Nov 9, 2026. Shares held after the trade: 7,651 (-19.9%).
Rain Enhancement Technologies Holdco received a deficiency notice from Nasdaq on November 6, 2026, because its Class A common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. The company has until May 5, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for at least ten consecutive business days.
Star Equity Holdings, Inc. reported a net loss of $1.59 million for the third quarter of 2026, compared to a $1.76 million loss in the prior year period, despite a 12.4% increase in total revenues to $53.9 million. The company's year-to-date net loss widened significantly to $7.23 million as operating expenses rose, particularly in salaries and general office costs.
Scribe Therapeutics reported a net loss of $33.0 million for the nine months ended September 30, 2026, compared to a $12.6 million loss in the prior year period, primarily due to a significant decrease in collaboration revenue. During the quarter, the company completed its initial public offering and concurrent private placement, resulting in a cash and cash equivalents balance of $172.1 million.
Adams Street Credit Solutions Fund (ASCEND) is a business development company that reported 3,326,403.646 Class I shares outstanding as of November 12, 2026. The filing indicates the fund is an emerging growth company and a non-accelerated filer, focusing on middle-market senior loans and secured debt investments.
Pinnacle West Capital Insider Paula J. Sims Sells $211K of Stock
Paula J. Sims sold 2,000 shares of Pinnacle West Capital Corp at $105.44 a share, worth $211K in total on Nov 9, 2026. Shares held after the trade: 9,032 (-18.1%).
For the fiscal year ended September 30, 2026, RMR Group Inc. reported total revenues of $643.2 million, an 8.2% decrease from the prior year, primarily driven by lower reimbursable costs. Net income attributable to the company fell 39.2% to $10.7 million, impacted by a $19.1 million impairment loss and increased interest expenses related to new property acquisitions.
Commercial Vehicle Group, Inc. finalized the specific share counts for inducement equity awards granted to its new President and CEO, David Ruppel. The awards include make-whole grants for forfeited equity from his previous employer and an initial long-term incentive award with a target value of $1.6 million, covering up to 2,175,614 shares at maximum performance.
Avidbank Holdings reported a significant regulatory shift as of September 30, 2026, with none of its reciprocal deposits classified as brokered deposits due to the 21st Century ROAD to Housing Act. This compares to $475.4 million in brokered deposits at year-end 2025. The company also recorded $1.3 million in bank-owned life insurance death benefits during the first nine months of 2026.
JLL Income Property Trust's Board of Directors declared a monthly distribution for November 2026 of $0.0525 per share and unit. The distribution is payable on or around November 24, 2026, to stockholders of record as of November 19, 2026, representing an annualized distribution rate of approximately 5.6% based on the current NAV.
SOLV Energy, Inc. is a non-accelerated filer reporting for the quarter ended September 30, 2026. The filing highlights risks related to project timing, labor costs, and material availability, while noting that the company has identified material weaknesses in its internal control over financial reporting.
Principal Credit Real Estate Income Trust reported net income of $6.93 million for the nine months ended September 30, 2026, a significant increase from $2.15 million in the prior year period. Total assets grew to $494.7 million, driven by investments in loans receivable, while the company continued to issue multiple classes of common shares to fund its real estate credit activities.
Ensysce Biosciences reported financial results for the third quarter of 2026, highlighting the completion of its acquisition of Cy Biopharma and the addition of lead asset CY200 for Complex Regional Pain Syndrome. The company ended the quarter with a strengthened cash position of $29.7 million and submitted a Phase 2a protocol for CY200 to the UK's MHRA.
Term
Q3 2026
“Ensysce is a fundamentally different company today than it was at the start of the year. With CY200, we now lead with a potentially first-in-class approach to CRPS, a devastating condition for which there is currently no FDA-approved therapy.”
Dr. Lynn Kirkpatrick, Chief Executive Officer
“Our priority since the acquisition has been to advance CY200 efficiently, and submitting the CYBIO 001 protocol to the MHRA in September was a significant first step.”
Aeva Technologies CTO Mina Rezk Sells $604K of Stock
Mina Rezk, CTO, sold 50,000 shares of Aeva Technologies, Inc. at $11.33 to $12.19 a share (average $12.08) in 2 transactions, worth $604K in total on Nov 9, 2026. Shares held after the trade: 1,556,669 (-2.7%).
Innventure, Inc. reported third quarter 2026 financial results, highlighting a strategic transformation to reduce parent-level costs and focus resources on its interest in Accelsius. The company reduced its headcount from 40 to 15 since Q1 and is evaluating strategic alternatives for its AeroFlexx and Refinity businesses to address near-term liquidity needs.
Term
3 months
“Over the last few months, our management team and Board have taken decisive steps to transform Innventure into a leaner, more focused organization, concentrating our resources on the opportunities we believe offer the clearest path to driving shareholder value.”
Bill Grieco, Chief Executive Officer of Innventure
“These actions share the common objective to preserve and maximize the value of our interest in Accelsius while giving the business the necessary resources to realize its full potential.”
Bill Grieco, Chief Executive Officer of Innventure
Crown Crafts Inc. reported net income of $1.3 million for the quarter ended September 27, 2026, compared to $1.2 million in the prior year period, despite a decrease in net sales from $23.7 million to $19.0 million. For the six-month period, net income significantly improved to $3.4 million from $53,000, driven by a substantial reduction in the cost of products sold and improved gross profit margins.
Jefferson Capital, Inc. reported total revenues of $539.5 million for the nine months ended September 30, 2026, an increase from $458.5 million in the prior year period, primarily driven by higher portfolio income. Total assets grew to $2.26 billion as of September 30, 2026, while stockholders' equity increased to $518.1 million.
AnaptysBio reported net income of $3.9 million for the quarter ended September 30, 2026, compared to $15.1 million in the prior year period. The company's financial structure has shifted significantly following the spin-off of its Biopharma segment, which is now presented as discontinued operations.
Cardiff Oncology reported Q3 2026 financial results and provided a clinical update on its Phase 2 trial of onvansertib in first-line RAS-mutated mCRC, noting that median PFS has not yet been reached in the 30 mg arm. The company is preparing for a registrational Phase 3 trial expected to start in Q1 2027 and reported a cash position of $68.1 million as of September 30, 2026.
Term
Q3 2026
“We’re greatly encouraged by the performance of onvansertib in first-line RAS-mutated mCRC. As the data mature, the benefit of onvansertib in combination with FOLFIRI/bev is becoming more evident, with growing separation between the onvansertib and control arms.”
Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology
“Building on the strength of these data, we are actively preparing for our upcoming registrational trial. There are currently no treatment options specifically approved for patients with pan RAS-mutated mCRC in the first-line setting and we believe onvansertib has the potential to become an important new treatment for these patients.”
Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology
United States Lime & Minerals President & CEO Timothy W. Byrne Sells $4.98M of Stock
Timothy W. Byrne, President & CEO, sold 42,000 shares of United States Lime & Minerals Inc at $118.54 to $119.93 a share (average $118.59) in 2 transactions, worth $4.98M in total on Nov 10, 2026. Shares held after the trade: 72,741 (-35.7%).
Roblox Chief Legal Off. & Corp. Sec. Mark Reinstra Sells $262K of Stock
Mark Reinstra, Chief Legal Off. & Corp. Sec., sold 5,071 shares of Roblox Corp at $51.08 to $52.05 a share (average $51.66) in 2 transactions, worth $262K in total on Nov 9, 2026. Shares held after the trade: 381,554 (-0.8%).
INNOVATE Corp. reported its third quarter 2026 financial results, highlighted by a 42.8% increase in revenue to $495.5 million and a return to profitability with net income of $15.8 million. During the period, the company executed major strategic divestitures, including the sale of a controlling interest in HC2 Broadcasting and the completion of the DBM Global sale to IES Holdings shortly after quarter-end.
Term
Q3 2026
“DBM Global capped its final quarter under our ownership with exceptional performance, and we took two significant steps to reshape our portfolio through the sale of a controlling interest in HC2 Broadcasting and, shortly after quarter-end, the sale of DBM Global to IES. These transactions mark meaningful progress in our efforts to unlock the value of our assets, generate funds to help address coming debt repayment and redemption obligations, and further simplify INNOVATE's portfolio and capital structure.”
Avie Glazer, Chairman of INNOVATE
“Our focus now turns to the opportunities within our remaining portfolio, addressing liquidity and continuing to maximize value for INNOVATE shareholders. MediBeacon continues to build commercial momentum and advance its commercialization efforts in the U.S. and China, while HC2 Broadcasting is actively pursuing initiatives to unlock greater potential for its spectrum assets.”
Sanara MedTech reported net revenue of $84.4 million for the nine months ended September 30, 2026, a 12% increase over the prior year. Despite higher gross profits, the company recorded a net loss of $1.4 million for the period, primarily due to increased selling, general, and administrative expenses and interest costs.
Lulu’s Fashion Lounge reported a 20% decline in Q3 2026 net revenue to $58.6 million, driven by lower order volumes and higher return rates. Despite the revenue headwind, the company achieved a 230-basis-point gross margin expansion and a 17% reduction in inventory as it continues an assortment reset strategy.
Term
Q3 2026
“During the third quarter, we continued to advance our assortment reset and saw encouraging signs from newer product, even as the impact of historical assortment decisions remained a headwind to customer engagement and repeat purchasing behavior. While these pressures continue to weigh on revenue, we are encouraged by the improving productivity and reorder eligibility of 2026 product introductions, which reinforces our confidence that refocusing the assortment on the categories and customers where Lulus has historically differentiated itself is the right path to rebuilding customer engagement over time.”
Crystal Landsem, CEO of Lulus
“Throughout the third quarter, we maintained a disciplined approach to inventory management, expense control and working capital as we continued to drive greater efficiency across the business.”
Codexis reported Q3 2026 revenue of $19.3 million, a significant increase from $8.6 million in the prior year, driven by higher product revenue from new customer launches. The company also highlighted a new $60 million term loan facility with Trinity Capital and the successful scale-up of its ECO Synthesis Manufacturing Platform to 100-gram scale.
Term
Q3 2026
“I am pleased with our outstanding progress in 2026, through both innovation and technical achievements, that has garnered attention from leading innovators in the siRNA field.”
Alison Moore, PhD, President and Chief Executive Officer
“We have made significant progress in industrializing our technology while simultaneously increasing our revenue base, managing expenses, and improving the financial stability of our company.”
Alison Moore, PhD, President and Chief Executive Officer
Decoy Therapeutics Inc. reported a net loss of $7.59 million for the nine months ended September 30, 2026, compared to a $3.54 million loss in the prior year period, driven by a significant increase in research and development expenses. The company recognized $535,059 in grant revenue during the period and maintains a cash balance of approximately $8.17 million as of September 30, 2026.
ImmuCell Corporation reported a settlement of $2.0 million with a former contract manufacturer and a $0.1 million regulatory fee reversal following the decision to cease focus on Re-Tain®. The company is currently refitting approximately $11.8 million in idle manufacturing assets for First Defense® production and reported anti-dilutive stock options totaling 968,978 for the quarter ended September 30, 2026.
VolitionRx reported total revenues of $3.0 million for the nine months ended September 30, 2026, a significant increase from $1.3 million in the prior year, primarily driven by product sales. Despite higher revenues, the company recorded a net loss of $17.8 million for the period, impacted by $15.9 million in operating expenses and $5.0 million in other expenses including debt extinguishment costs.
SoundThinking reported a net loss of $20.2 million for the first nine months of 2026, a significant increase from the $6.6 million loss in the prior year period, driven by a decline in revenues and higher general and administrative expenses. The company also announced a pending acquisition by Transom Capital Group, LLC, which has introduced uncertainties regarding the transaction's completion and its impact on business operations.
Ruben Baldew, CFO, bought 8,379 shares of Nomad Foods Ltd at $11.95 a share, worth $100K in total on Nov 9, 2026. Shares held after the trade: 375,551 (+2.3%).